Actinobacteriota

Actinobacteriota includes Bifidobacterium, which appears in many probiotic products, alongside bacteria with quite different effects. Its percentage in stool can change with diet, age, medication, and illness. A change in the total doesn't tell you which members changed or whether your health improved.

This is an exploratory microbiome marker. It has no validated healthy target, and screening or treatment guided by this percentage hasn't been shown to improve health outcomes.

What the Number Represents

Actinobacteriota is a phylum. A phylum is one of the broad branches on the bacterial family tree. Actinobacteria and Actinomycetota are alternative names you'll encounter. Its gut members include Bifidobacterium, Collinsella, Eggerthella, and Actinomyces.

The stool result reports relative abundance. This is the estimated percentage of the bacterial community assigned to this phylum through analysis of bacterial DNA. It isn't an absolute count of living bacteria. A decrease can happen because other bacteria expanded, even when the number of bacteria in this group stayed the same.

Stool samples represent bacteria shed into the intestinal contents. They don't fully represent bacteria attached to the gut lining. A study comparing stool with tissue samples from the intestinal lining found clearer inflammatory bowel disease differences in the tissue samples, so results from gut tissue or mouth samples can't be treated as equivalent to this stool measurement.

Why Individual Members Matter

Some Bifidobacterium species break down carbohydrates from plants, and others can use sugars in breast milk. They produce small acids called acetate and lactate.

In laboratory cultures of bacteria isolated from the human gut, other species used those acids to make butyrate. Butyrate provides fuel for cells lining the colon.

That mechanism helps explain interest in these bacteria, but a phylum percentage doesn't measure butyrate production or the condition of your gut lining. Species and strains differ, and evidence about a particular Bifidobacterium strain doesn't establish a benefit from increasing the entire phylum.

How Age Shapes the Result

Infancy is a period of rapid change. Bifidobacterium can dominate the stool of breastfed babies, and longitudinal research has found that its abundance falls after breastfeeding stops. That finding concerns one genus within the phylum, and infant patterns aren't a target for adults.

Some members also become less common with age in adulthood. A large study using whole-genome stool sequencing found age-related decreases in several Actinobacteriota species, including Bifidobacterium. A separate small pilot reported about 2.4 times as much of the total phylum in younger adults as in older adults, but that difference wasn't statistically significant. Neither finding establishes how much your own result should decline or makes a low result a deficiency.

Bowel Disease and Gut Inflammation

The direction differs between studies. A small Chinese study found lower stool abundance in Crohn's disease. A Polish ulcerative colitis pilot found roughly three times the share seen in healthy controls. Another study across inflammatory bowel disease cohorts linked higher abundance to greater disease severity.

These findings don't supply a rule that a higher or lower percentage is healthier. Illness, its treatment, diet, and differences in the bacteria included in the total can all affect comparisons. Even Bifidobacterium was more abundant in a small study of Behçet's disease, alongside Eggerthella. Behçet's disease causes inflammation in several parts of the body. These associations don't establish that the bacteria caused the illness.

Weight, Blood Sugar, and Kidney Disease

A study of Thai children with obesity found that lower phylum abundance went with higher body weight, fasting insulin, and insulin resistance. Its comparison with children without obesity used data from an earlier study. Across eight European adult cohorts, higher BMI was associated with greater odds of detecting Collinsella. That is a finding about one genus within the phylum, so it doesn't establish the direction of risk for the phylum total.

A study following 115 people on hemodialysis linked a narrower bacterial class called Actinobacteria to the development of protein-energy wasting. This condition involves loss of muscle and nutritional reserves. The class used in that analysis is only part of the phylum measured here. Higher class abundance was associated with lower odds of developing wasting, but the estimate was uncertain and doesn't establish a protective effect or a treatment target for this stool result.

Mood, Allergies, and Other Associations

A stool sequencing study of women with major depression found lower phylum abundance than in healthy women. Across depression studies, however, findings have gone in both directions. Lower abundance has also been reported in allergic rhinitis and in a small long COVID study.

These are associations in people who were already ill. They don't establish that changing this percentage would prevent or treat depression, allergies, or long COVID, and they don't validate it as a diagnostic test for those conditions.

Babies, Vaccines, and Early Illness

In a hospital cohort of 310 newborns, those who developed necrotizing enterocolitis or feeding intolerance had less of this phylum in their first stool. Necrotizing enterocolitis is a serious bowel disease that mainly affects premature babies. The study examined stool collected shortly after birth, and the affected babies differed in other ways, including gestational age. These findings don't transfer directly to stool testing later in life.

Among 48 Bangladeshi infants, higher stool Actinobacteria abundance was associated with stronger responses to several vaccines. Bifidobacterium dominated these samples and was also associated with thymus size. The thymus is an organ where some immune cells mature. These observations don't prove that a higher stool percentage improves vaccine protection.

A separate study of breastfed Danish infants associated higher early phylum abundance with later fever episodes. The differing findings illustrate why an infant's phylum percentage cannot be read as a general measure of immune strength.

Cancer and Transplant Research

In a study using 813 stool samples collected for fecal blood testing, researchers found differences in the phylum and in Collinsella and developed models combining several bacterial measurements to identify colorectal lesions. This was research on a combined model. It didn't validate this phylum result alone as a cancer screening test.

Studies of liver cancer immunotherapy have also reported greater phylum abundance among people whose cancer responded. The available studies are observational and use differing stool profiling methods. They don't establish that increasing the phylum improves treatment response or that the result should determine which cancer treatment you receive.

After donor stem cell transplantation, a study linked particular bacteria in stool, including Rothia mucilaginosa, with severe graft-versus-host disease. This is a complication in which donor immune cells attack the recipient's tissues. Rothia belongs to this phylum, but a species-level association cannot be applied to the phylum total.

What Longer Studies Can Establish

A Finnish population study followed adults for about 15 years. Its mortality associations centered on a different bacterial family called Enterobacteriaceae. It wasn't a validation of Actinobacteriota as a standalone longevity test.

A genetic analysis using inherited differences associated with gut bacteria found no strong evidence that the microbial features studied had large causal effects on chronic disease or longevity. Genetic predictors of bacterial abundance were limited, so the findings also couldn't rule out smaller or more specific effects. This indirect evidence doesn't establish a desirable percentage for your stool result.

When Results Can Be Misleading

• Changes elsewhere in the community: this result is a percentage. Other bacteria can change the denominator without changing this group's absolute abundance.
• Recent diet changes: controlled human feeding studies show that stool communities can change rapidly and return toward their earlier pattern after the experimental diet ends. These findings don't predict a fixed change in this phylum after a particular meal.
• Stool consistency: how quickly material passes through the bowel is associated with the bacteria found in stool. Differences between loose and firm samples can complicate comparisons.
• Laboratory methods: DNA extraction, the region analyzed, and the reference database can affect the reported percentage. Sequencing a bacterial marker gene and sequencing DNA across whole genomes can give different estimates.
• Taxonomic level: a result for Bifidobacterium, Collinsella, or a class named Actinobacteria covers a narrower group than this phylum. Those results cannot substitute for its total.
• Collection and storage: contamination or storage outside the collection kit's instructions can distort the bacterial profile.

Tracking Your Trend

Healthy adults often retain a personal pattern of gut bacteria despite short-term variation. Repeated measurements can help describe whether a change persists, especially when the same collection and analysis methods are used. There is no validated size of change in this phylum that establishes recovery, deterioration, or a successful supplement.